The FDA has approved tirzepatide (Zepbound) as the first and only medication for obstructive sleep apnea in adults with ...

Imlunestrant, an oral SERD, significantly prolonged progression-free survival in patients with advanced ER+, HER2- breast ...

The US FDA has approved BRAFTOVI® (encorafenib) with cetuximab and mFOLFOX6 as a first-line therapy for BRAF V600E-mutant ...

We are honored to host Carter Keller, Head of GigaGen and Senior Vice President at Grifols, as we delve into the ...

AbbVie has announced plans to acquire Nimble Therapeutics in a $200 million deal. The acquisition brings Nimble’s pioneering oral peptide IL23R inhibitor, currently in preclinical development for ...

Novartis announced that its drug Ribociclib (Kisqali®) combined with endocrine therapy (ET) demonstrates a sustained 28.5% reduction in distant recurrence for high-risk HR+/HER2- early breast cancer ...

Synaffix announces that it has entered into a licensing agreement with Elevation Oncology to develop EO-1022, a HER3-targeting Antibody-Drug Conjugate (ADC) leveraging Synaffix’s advanced platform ...

The Phase 3 PATINA Trial shows that adding palbociclib (IBRANCE®) to standard maintenance therapy significantly extends progression-free survival (PFS) in HR+, HER2+ metastatic breast cancer.

Merck has announced a significant milestone in the treatment of advanced epithelial ovarian cancer. The Phase 3 KEYLYNK-001 trial demonstrated that KEYTRUDA® (pembrolizumab) plus chemotherapy, ...